Literature DB >> 32774227

Reply to the Correspondence by Untch et al. "Concerning Dediu M, Zielinski C: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer" [Breast Care 2019; DOI 10.1159/000500624].

Mircea Dediu1, Christoph Zielinski2.   

Abstract

Entities:  

Year:  2019        PMID： 32774227      PMCID： PMC7383268          DOI： 10.1159/000502508

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  20 in total

Review 1.  Biomarker: Predictive or Prognostic?

Authors:  Karla V Ballman
Journal:  J Clin Oncol       Date:  2015-09-21       Impact factor: 44.544

Review 2.  Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies.

Authors:  Alfredo Berruti; Vito Amoroso; Fabio Gallo; Valentina Bertaglia; Edda Simoncini; Rebecca Pedersini; Laura Ferrari; Alberto Bottini; Paolo Bruzzi; Maria Pia Sormani
Journal:  J Clin Oncol       Date:  2014-10-27       Impact factor: 44.544

3.  Is It Time to Redefine Prognostic and Predictive in Oncology?

Authors:  Mark Minden
Journal:  J Clin Oncol       Date:  2016-03-14       Impact factor: 44.544

4.  Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Authors:  José Baselga; Ian Bradbury; Holger Eidtmann; Serena Di Cosimo; Evandro de Azambuja; Claudia Aura; Henry Gómez; Phuong Dinh; Karine Fauria; Veerle Van Dooren; Gursel Aktan; Aron Goldhirsch; Tsai-Wang Chang; Zsolt Horváth; Maria Coccia-Portugal; Julien Domont; Ling-Min Tseng; Georg Kunz; Joo Hyuk Sohn; Vladimir Semiglazov; Guillermo Lerzo; Marketa Palacova; Volodymyr Probachai; Lajos Pusztai; Michael Untch; Richard D Gelber; Martine Piccart-Gebhart
Journal:  Lancet       Date:  2012-01-17       Impact factor: 79.321

Review 5.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

Authors:  Patricia Cortazar; Lijun Zhang; Michael Untch; Keyur Mehta; Joseph P Costantino; Norman Wolmark; Hervé Bonnefoi; David Cameron; Luca Gianni; Pinuccia Valagussa; Sandra M Swain; Tatiana Prowell; Sibylle Loibl; D Lawrence Wickerham; Jan Bogaerts; Jose Baselga; Charles Perou; Gideon Blumenthal; Jens Blohmer; Eleftherios P Mamounas; Jonas Bergh; Vladimir Semiglazov; Robert Justice; Holger Eidtmann; Soonmyung Paik; Martine Piccart; Rajeshwari Sridhara; Peter A Fasching; Leen Slaets; Shenghui Tang; Bernd Gerber; Charles E Geyer; Richard Pazdur; Nina Ditsch; Priya Rastogi; Wolfgang Eiermann; Gunter von Minckwitz
Journal:  Lancet       Date:  2014-02-14       Impact factor: 79.321

6.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

Authors:  Carsten Denkert; Sibylle Loibl; Aurelia Noske; Marc Roller; Berit Maria Müller; Martina Komor; Jan Budczies; Silvia Darb-Esfahani; Ralf Kronenwett; Claus Hanusch; Christian von Törne; Wilko Weichert; Knut Engels; Christine Solbach; Iris Schrader; Manfred Dietel; Gunter von Minckwitz
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

Review 7.  A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer.

Authors:  Mircea Dediu; Christoph Zielinski
Journal:  Breast Care (Basel)       Date:  2019-05-27       Impact factor: 2.860

Review 8.  Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review.

Authors:  Sasha E Stanton; Sylvia Adams; Mary L Disis
Journal:  JAMA Oncol       Date:  2016-10-01       Impact factor: 31.777

9.  Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

Authors:  Gunter von Minckwitz; Chiun-Sheng Huang; Max S Mano; Sibylle Loibl; Eleftherios P Mamounas; Michael Untch; Norman Wolmark; Priya Rastogi; Andreas Schneeweiss; Andres Redondo; Hans H Fischer; William Jacot; Alison K Conlin; Claudia Arce-Salinas; Irene L Wapnir; Christian Jackisch; Michael P DiGiovanna; Peter A Fasching; John P Crown; Pia Wülfing; Zhimin Shao; Elena Rota Caremoli; Haiyan Wu; Lisa H Lam; David Tesarowski; Melanie Smitt; Hannah Douthwaite; Stina M Singel; Charles E Geyer
Journal:  N Engl J Med       Date:  2018-12-05       Impact factor: 176.079

10.  Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers.

Authors:  Miao Ruan; Tian Tian; Jia Rao; Xiaoli Xu; Baohua Yu; Wentao Yang; Ruohong Shui
Journal:  Diagn Pathol       Date:  2018-08-31       Impact factor: 2.644
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.